Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.
You may also be interested in...
Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch
The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.
Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch
The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.
Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter
Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10